Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Location of Lesions Responsible for Blood Loss in the Gastrointestinal (GI) Tract

Eligibility criteria:
Inclusion Criteria:

          -  Male and female patients aged 18 years and over and up to but not exceeding 80 years

          -  Patients presenting with IDA whom require gastroscopy and colonoscopy as per national
             guidelines (1)

        Exclusion Criteria:

          -  Patients who have contraindications to gastroscopy or colonoscopy

          -  Patients under the age of 18 years

          -  Patients over the age of 80 years

          -  Active vomiting

          -  Patients with a permanent pacemaker, implantable cardioverter-defibrillator or REVEAL
             device

          -  Patients with any electronic/magnetic/mechanically controlled devices e.g. sacral
             nerve stimulators, bladder stimulators

          -  Patients with dysphagia, odynophagia or known swallowing disorder

          -  Patients with known Zenker's diverticulum

          -  Patients with suspected bowel obstruction or bowel perforation

          -  Patients with prior bowel obstruction

          -  Patients with gastroparesis or known gastric outlet obstruction

          -  Patients with known Crohn's disease

          -  Patients who are taking daily non-steroidal anti-inflammatory drugs (excluding
             prophylactic doses of aspirin) for more than six months

          -  Patients who have received abdominopelvic radiotherapy treatment

          -  Patients with a history of GI tract surgery (Billroth I, Billroth II, Oesophagectomy,
             gastrectomy or bariatric procedure)

          -  Patients that are pregnant or lactating

          -  Patients with altered mental status that would limit their ability to swallow

          -  Patients with allergy to conscious sedation, polyethylene glycol or metoclopramide

          -  Patients unwilling to swallow the capsule

          -  Patients with known dementia affecting ability to consent

          -  Patients who are unable to understand or speak English

          -  Patients unable to provide written informed consent
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 80 Years

Eligibility (NLI label): Entailment